Eli Lilly and Company $LLY Holdings Lifted by Sax Wealth Advisors LLC

Sax Wealth Advisors LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 450.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,410 shares of the company’s stock after acquiring an additional 6,881 shares during the quarter. Sax Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $9,731,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Bank of America Corp DE bought a new position in Eli Lilly and Company during the second quarter valued at $13,522,666,000. Jupiter Topco LLC purchased a new position in Eli Lilly and Company during the second quarter worth about $4,667,180,000. Fifth Third Bancorp boosted its position in shares of Eli Lilly and Company by 321.3% during the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock valued at $1,805,959,000 after acquiring an additional 1,497,423 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Eli Lilly and Company by 353.7% in the first quarter. Assenagon Asset Management S.A. now owns 1,550,234 shares of the company’s stock valued at $1,425,859,000 after purchasing an additional 1,208,510 shares in the last quarter. Finally, Corient Private Wealth LP purchased a new position in Eli Lilly and Company in the 2nd quarter worth approximately $764,116,000. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on LLY. Wells Fargo & Company increased their price objective on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Citigroup upped their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the company a “buy” rating in a research report on Thursday, September 17th. Morgan Stanley upped their target price on shares of Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Finally, Berenberg Bank set a $1,400.00 price objective on shares of Eli Lilly and Company and gave the company a “buy” rating in a research report on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,313.43.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 over the last 90 days. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong obesity-drug pipeline remains the key catalyst. Investors are focusing less on Eli Lilly’s October 29 earnings report and more on retatrutide, an investigational next-generation obesity treatment that could become a larger growth driver than Zepbound if late-stage results confirm its potential. Retatrutide and earnings article
• Positive Sentiment: Revenue and earnings expectations are rising. Analysts at Erste Group modestly increased their FY2026 EPS forecast to $36.55 and FY2027 estimate to $47.30. Separately, RBC said strong diabetes and weight-loss sales could lead Lilly to raise its full-year revenue outlook, which is projected to reach as much as $87 billion. Lilly revenue outlook article
• Positive Sentiment: Analyst support remains favorable. Royal Bank of Canada reaffirmed its “Outperform” rating and established a $1,500 price target. Lilly also received an A+ profitability grade among mega-cap healthcare companies. RBC rating article
• Positive Sentiment: Additional pipeline and partnership developments support long-term growth. Prelude Therapeutics is collaborating with Lilly to evaluate its cancer drug candidate PRT13722 alongside Lilly therapies Verzenio and Inluriyo in breast cancer patients. New Phase 3b data also indicated that combining Taltz and Zepbound improved psoriasis outcomes and reduced weight in studied patients. Prelude collaboration article
• Neutral Sentiment: A potential stock split is speculative. Lilly’s share price could support a split, but management has not announced one, and such an action would not change the company’s underlying value. Stock split article
• Negative Sentiment: Retatrutide’s clinical profile still carries risk. A drug combination generated more weight loss than Zepbound alone, but discontinuation rates were substantially higher, raising questions about tolerability and commercial adoption. Lilly is also contending with illicit online sales of retatrutide before launch. Weight-loss combination article
• Negative Sentiment: Profit-taking and valuation pressure may be weighing on the stock. After a major multiyear rally, investors may be locking in gains ahead of earnings, leaving Lilly vulnerable if results or guidance fail to exceed already-high expectations.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded down $11.77 during mid-day trading on Tuesday, hitting $1,170.85. The stock had a trading volume of 605,069 shares, compared to its average volume of 2,945,758. Eli Lilly and Company has a one year low of $783.85 and a one year high of $1,292.65. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The firm has a market capitalization of $1.10 trillion, a P/E ratio of 39.34, a P/E/G ratio of 1.47 and a beta of 0.46. The firm’s 50 day moving average is $1,175.57 and its 200 day moving average is $1,100.31.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The firm had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. During the same quarter last year, the business posted $6.31 earnings per share. The firm’s revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 36.19 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.